您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Deferasirox-d4
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Deferasirox-d4
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Deferasirox-d4图片
CAS NO:1133425-75-8
包装与价格:
包装价格(元)
500μg电议
1mg电议

产品介绍
Deferasirox-d4 是标记为 Deferasirox 的氘。 Deferasirox (ICL 670) 是一种口服铁螯合剂,用于治疗输血性铁过载。
Cas No.1133425-75-8
别名地拉罗司 d4
Canonical SMILESOC(C(C([2H])=C1[2H])=C([2H])C([2H])=C1N2C(C3=C(O)C=CC=C3)=NC(C4=C(O)C=CC=C4)=N2)=O
分子式C21H11D4N3O4
分子量377.4
溶解度DMF: 30 mg/ml,DMSO: 20 mg/ml,Ethanol: 2 mg/ml
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Deferasirox-d4 is intended for use as an internal standard for the quantification of deferasirox by GC- or LC-MS. Deferasirox is a synthetic, tridentate iron chelator that binds iron at a 2:1 ratio. It is selective for iron (Fe(III)) over Cu(II), Zn(II), Mg(II), and Ca(II) but does bind to Al(III). Deferasirox decreases iron levels in iron-loaded rat heart cells in vitro by 45.8 and 55.6% compared to control levels when used at concentrations of 160 and 320 µM, respectively. In hypertransfused rats, deferasirox (200 mg/kg) decreases radiolabeled liver iron levels from 41 to 21.7% and blood iron levels from 8.2 to 3.4%. It is primarily excreted via the fecal route, in contrast to the iron chelator deferoxamine . Deferasirox also inhibits proliferation of SAS human oral squamous carcinoma cells (EC50 = 21 µM), decreases cyclin D1 protein levels, and increases protein levels of N-Myc downregulated gene 1 (NDRG1) and NDRG3. It acts in a synergistic manner when used in combination with gemcitabine to reduce proliferation of BxPC-3 pancreatic cancer cells in vitro and reduce tumor growth in a BxPC-3 mouse xenograft model when administered at a dose of 200 mg/kg. Formulations containing deferasirox have been used in the treatment of β-thalassemia and chronic iron overload.